Skip to content
Screener

Boston Scientific BSX Cardiac Rhythm Management — Net Sales

Other product segments

Interventional Cardiology & Vascular Therapies
$4.64B—
Electrophysiology
$905M+24.0%
Endoscopy
$736M+9.4%
Urology
$646M+2.1%
Watchman
$506M+19.1%
Neuromodulation
$318M+17.3%
Interventional Oncology & Embolization
$214M—

Similar metrics at other companies

ITG
ITGRCardiac Rhythm Management & Neuromodulation — Sales
$168.26M+4.9%
ITG
ITGRCardiac Rhythm Management & Neuromodulation — Total sales
$168.26M+4.9%
Nature's Sunshine Products logo
NATRWeight management — Net Sales
$3.86M-13.4%
Alamo Group logo
ALGVegetation Management — Net Sales
$175.42M+7.0%
AVN
AVNSTotal Pain Management and Recovery — Net Sales
$56.3M+0.2%
General Mills logo
GISPet — Net Sales
$746.6M+5.8%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$69.46B-56.1%
P/E18.9×-44.4×
P/S3.3×-5.3×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
BusinessesThree Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / Int'lThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / Int'lThree Months Ended March 31, 2025 / Total
MedSurg1,1475541,7011,0934841,577
Interventional Cardiology & Vascular Therapies5526921,2444676571,124
Watchman4624450639034425
Electrophysiology603302905511219730
Cardiac Rhythm Management349229578358220578
Interventional Oncology & Embolization1709926814287228
Cardiovascular2,1371,3663,5031,8681,2183,085
Total Net Sales$3,284$1,920$5,203$2,960$1,702$4,663

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's cardiac rhythm management — net sales?
Boston Scientific (BSX) reported cardiac rhythm management — net sales of $578M in Q1 2026.
How has Boston Scientific's cardiac rhythm management — net sales changed year-over-year?
Boston Scientific's cardiac rhythm management — net sales decreased by 0.0% year-over-year, from $578M to $578M.
What is the long-term trend for Boston Scientific's cardiac rhythm management — net sales?
Over 4 years (2021 to 2025), Boston Scientific's cardiac rhythm management — net sales has grown at a 3.7% compound annual growth rate (CAGR), from $2.02B to $2.33B.
What does cardiac rhythm management — net sales mean?
This metric represents the total revenue generated from the sale of medical devices and systems designed to monitor and treat heart rhythm disorders, such as pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices. It reflects the market demand for the company's cardiac rhythm management portfolio and the effectiveness of its commercial strategy in the electrophysiology and heart failure markets. This revenue stream is a critical indicator of the company's competitive position in the cardiovascular medical device sector.

Ask your AI about Boston Scientific's cardiac rhythm management — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude